You just have set the baseline ( dont put trading hat and look at it with tinted glass), this is the baseline " aim is to evaluate safety, tolerability, and preliminary efficacy", lets go now one by one on how its checked and boxes are ticked...
1. Immune Response - It stimulates the immune response and increased the T cell activation and targetted the cancer cells (tick in the box) 2. Tumor Shrinkage or Stabilization - patients exhibited partial or complete responses (tumor shrinkage) or stable disease (halted tumor growth) (tick in the box) 3. Safety Profile - the vaccine is well-tolerated, with manageable side effects like mild fever, injection site reactions, fatigue etc, here the highligth is manageable side effects no myelosuppression which is the biggest victory for doctors, ask any one of them even to your GP he will say what a death sentence myelosuppression is.. (tick in the box) 4.Biomarker Indicators - Initial efficacy correlated with biomarker improvement like reduced levels of tumor markers in the blood (tick in the box)
IMU Price at posting:
3.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)